藥物傳遞領域的合作與授權協議（2019-2026 年）

藥物配送交易的關鍵指標

該藥物傳輸領域的合作以能夠實現和增強治療效果的平台技術為中心，其交易結構體現了在輸送系統、製劑技術和給藥途徑方面的創新。

本報告對超過 1350 項藥物輸送合作和許可協議進行了全面系統的分析，清晰且有實證支持地闡述了整個市場夥伴關係的設計、談判和執行方式。

清楚了解市場標準

本報告將使您準確了解藥品運輸交易的實際結構，使您能夠：

• 自信地對標類似交易
• 對相關交易中的預付款、里程碑付款和特許權使用費結構進行詳細分析。
• 設定切合實際的市場參數
• 您可以清楚地了解合約條款如何因技術類型、應用和合作夥伴情況而異。
• 支持基於證據的評估和合約結構確定。
• 內部討論應基於實際交易數據，而非假設。
• 了解大型公司如何處理交易
• 在技​​術主導的跨治療環境中，可視化合作夥伴行為和重複交易結構。
• 全面了解交易結構和執行情況
• 本報告超越了表面的交易數據，提供了對底層合約文件的訪問，從而可以詳細了解實際合約是如何構建的。

這包括：

• 授予和保留的權利
• 負責開發和商業化
• 財務結構和支付觸發機制
• 關鍵合約條款和保障措施
• 這種程度的透明度對於了解藥物輸送夥伴關係中價值、風險和控制權的分配至關重要，尤其是在平台准入和整合到更廣泛的治療方案中是關鍵考慮因素的情況下。
• 專為實際業務發展和策略制定而設計。

本報告主要廣泛用於以下用途：

• 建構和基準化正在進行的交易
• 在清晰的市場環境下準備談判
• 對技術合作夥伴關係和交易對象的評估
• 支持以可靠證據為基礎的數據驅動型內部策略。
• 內容
• 超過 1350 項與藥物輸送相關的合作和許可協議。
• 財務條款，包括預付款、里程碑付款和版稅（如有揭露）。
• 一個可全文搜尋的合約目錄（依公司、技術和應用程式分類）。
• 可直接查閱向美國證券交易委員會提交的合約和原始文件。
• 交易趨勢分析、關鍵交易案例分析和活躍交易相關人員分析。
• 關於藥品傳輸領域交易的可靠、基於證據的參考資料。
• 本報告結合全面的交易覆蓋範圍和合約層面的洞察，為如何在藥物傳輸領域建立、談判和評估夥伴關係提供了可靠的、基於證據的參考資料。

目錄

執行摘要

第1章：引言

第2章：藥物輸送交易趨勢

• 介紹
• 長期藥物傳輸合約
• 大多數活躍的藥物輸送營運商
• 藥品配送交易（依交易類型）
• 藥物輸送交易（按治療領域分類）
• 藥物輸送交易（按行業分類）
• 藥品配送合約的條款與條件

第3章 主要藥物輸送合約

• 介紹
• 按價格範圍分類的頂級藥品配送服務

第4章：藥物輸送貿易中最活躍的相關人員

• 介紹
• 大多數活躍的藥物輸送營運商
• 最活躍的藥物輸送企業的公司簡介

第5章：藥品運輸合約交易目錄

• 介紹
• 藥品配送合約交易目錄

第6章：按技術類型分類的藥物輸送交易

• 交易清單
• 交易清單 - AZ 藥品配送交易（依公司分類）
• 交易清單 - 藥品配送交易（依交易類型）
• 交易清單 - 藥物輸送交易（按治療領域分類）
• 交易類型的定義
• 關於這家研究公司
• 當前夥伴關係
• 目前合約
• 理想合作夥伴最新報告的標題

The definitive benchmark for drug delivery dealmaking

Drug delivery partnering is centred around platform technologies that enable and enhance therapeutic performance, with deal structures reflecting access to delivery systems, formulation expertise, and route-of-administration innovation.

This report provides a comprehensive and structured analysis of 1350+ drug delivery collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how drug delivery deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by technology type, application, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a technology-driven and cross-therapeutic landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within drug delivery partnerships, particularly where platform access and integration into broader therapeutic programs are key considerations.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark live transactions
• Prepare for negotiations with well-defined market context
• Evaluate technology partnerships and counterparties
• Support internal strategy with robust, defensible data
• What's included
• 1350+ drug delivery collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, technology, and application)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for drug delivery dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how drug delivery partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in drug delivery dealmaking

• 2.1. Introduction
• 2.2. Drug delivery deals over the years
• 2.3. Most active drug delivery dealmakers
• 2.4. Drug delivery deals by deal type
• 2.5. Drug delivery deals by therapy area
• 2.6. Drug delivery deals by industry sector
• 2.7. Deal terms for drug delivery deals
  • 2.7.1 Drug delivery deals headline values
  • 2.7.2 Drug delivery deal upfront payments
  • 2.7.3 Drug delivery deal milestone payments
  • 2.7.4 Drug delivery royalty rates

Chapter 3 - Leading drug delivery deals

• 3.1. Introduction
• 3.2. Top drug delivery deals by value

Chapter 4 - Most active drug delivery dealmakers

• 4.1. Introduction
• 4.2. Most active drug delivery dealmakers
• 4.3. Most active drug delivery deals company profiles

Chapter 5 - Drug delivery contracts dealmaking directory

• 5.1. Introduction
• 5.2. Drug delivery contracts dealmaking directory

Chapter 6 - Drug delivery dealmaking by technology type

• Deal directory
• Deal directory - Drug delivery deals by company A-Z
• Deal directory - Drug delivery deals by deal type
• Deal directory - Drug delivery deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Drug delivery deals since 2019
• Figure 2: Active drug delivery dealmaking activity since 2019
• Figure 3: Drug delivery deals by deal type since 2019
• Figure 4: Drug delivery deals by therapy area since 2019
• Figure 5: Drug delivery deals by industry sector since 2019
• Figure 6: Drug delivery deals with a headline value
• Figure 7: Drug delivery deals with an upfront value
• Figure 8: Drug delivery deals with a milestone value
• Figure 9: Drug delivery deals with a royalty rate value
• Figure 10: Top drug delivery deals by value since 2019
• Figure 11: Most active drug delivery dealmakers since 2019
• Figure 12: Drug delivery deals by technology type since 2019